NFKB1 and rheumatoid arthritis: This drug is a selective IKKβ inhibitor, blocks IκBα phosphorylation, and prevents NF-κB p65 nuclear translocation, and its prodrug is under assessment in a clinical trial for inflammation-related cardiovascular diseases and rheumatoid arthritis [19, 20].